Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLENISH: Estradiol and Progesterone for VMS
NCT01942668Phase 3Completed
- Sponsor
- TherapeuticsMD
- Start
- Aug 2013
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of estradiol + progesterone in vasomotor symptoms (5 arms), sponsored by TherapeuticsMD. Primary endpoints: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS) at Week 12, Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS) at Week 12 and 1 more. Started Aug 2013; status: completed.
02
Drugs
estradiol + progesterone
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT01942668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01942668.